点击关注大松树,获取一手深度分析天风证券医药团队杨松/曹文清如您需要完整版报告,可联系天风证券医药团队或您对口销售报告摘要事件:近期,FGFR4抑制剂ABSK011联合阿替利珠单抗治疗FGF19过表达的晚期肝细胞癌(HCC)的Ⅱ期临床研究(ABSK-011-201)结果,在ESMO GI 2025上发布,展现了该疗法的临床潜力,研究入选ESMO GI 2025官方汇总的“Top Trials”试验...
Source Link点击关注大松树,获取一手深度分析天风证券医药团队杨松/曹文清如您需要完整版报告,可联系天风证券医药团队或您对口销售报告摘要事件:近期,FGFR4抑制剂ABSK011联合阿替利珠单抗治疗FGF19过表达的晚期肝细胞癌(HCC)的Ⅱ期临床研究(ABSK-011-201)结果,在ESMO GI 2025上发布,展现了该疗法的临床潜力,研究入选ESMO GI 2025官方汇总的“Top Trials”试验...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.